Great Lakes Advisors LLC Sells 11,129 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Great Lakes Advisors LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.3% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 197,419 shares of the medical research company’s stock after selling 11,129 shares during the quarter. Thermo Fisher Scientific makes up approximately 1.0% of Great Lakes Advisors LLC’s investment portfolio, making the stock its 25th largest holding. Great Lakes Advisors LLC owned about 0.05% of Thermo Fisher Scientific worth $109,173,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. One Wealth Management Investment & Advisory Services LLC grew its stake in shares of Thermo Fisher Scientific by 4.3% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 2,362 shares of the medical research company’s stock worth $1,306,000 after acquiring an additional 98 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in shares of Thermo Fisher Scientific by 47.4% during the second quarter. Los Angeles Capital Management LLC now owns 5,643 shares of the medical research company’s stock worth $3,121,000 after acquiring an additional 1,815 shares during the last quarter. Cullen Frost Bankers Inc. grew its stake in shares of Thermo Fisher Scientific by 2.8% during the second quarter. Cullen Frost Bankers Inc. now owns 27,831 shares of the medical research company’s stock worth $15,391,000 after acquiring an additional 764 shares during the last quarter. Lake Street Advisors Group LLC grew its stake in shares of Thermo Fisher Scientific by 3.2% during the second quarter. Lake Street Advisors Group LLC now owns 4,172 shares of the medical research company’s stock worth $2,309,000 after acquiring an additional 130 shares during the last quarter. Finally, UNIVEST FINANCIAL Corp boosted its position in Thermo Fisher Scientific by 1.0% in the second quarter. UNIVEST FINANCIAL Corp now owns 11,225 shares of the medical research company’s stock valued at $6,207,000 after buying an additional 110 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $180,255.00. Following the completion of the transaction, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $76,420,473.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now owns 17,887 shares of the company’s stock, valued at approximately $10,747,403.95. The disclosure for this sale can be found here. Insiders sold 23,084 shares of company stock worth $14,094,292 in the last three months. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Up 0.7 %

NYSE:TMO traded up $4.45 during trading hours on Friday, hitting $611.33. The company had a trading volume of 1,868,789 shares, compared to its average volume of 938,285. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a 50-day moving average of $584.07 and a 200 day moving average of $577.99. The company has a market cap of $233.35 billion, a P/E ratio of 39.21, a P/E/G ratio of 2.85 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share for the quarter, topping analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company’s revenue was down 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $5.15 EPS. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent research reports. Raymond James upped their target price on Thermo Fisher Scientific from $650.00 to $660.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Royal Bank of Canada boosted their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a report on Thursday, July 25th. Evercore ISI decreased their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Barclays decreased their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Finally, Robert W. Baird upped their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $630.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.